Publications

Posters

For copies of any of the following posters, please Email Us.

  • Big Data vs. Bad Bugs: Fighting ESKAPE Pathogens Electronically
  • Dabigatran Versus Warfarin Among Patients With Atrial Fibrillation: Real-World Post-market Results
  • Dronedarone or Amiodarone and Risk of Heart Failure HF: A Federal Partners Collaboration
  • DoD Mother-Child Database Approaches and Methods to Evaluate the Safety of Drugs and Biological Products During Pregnancy in the Post-Approval Setting
  • Varenicline and Potential Implications for Serious Neuropsychiatric and Cardiovascular Events
  • Advanced Visualization Analysis for Investigating Complex Adverse Drug Reactions in Claims Data
  • Proton Pump Inhibitors and Risk of Fractures
  • Prevalence of Tobacco Use and Cessation among the Military Health Service Population, 2010 - 2014 

Papers

FileDescriptionDate
Neuropsychiatric events in varenicline and nicotine replacement patch users in the Military Health SystemTo determine the rate ratio of neuropsychiatric hospitalizations in new users of varenicline compared to new users of nicotine replacement therapy (NRT) patch in the Military Health System (MHS).1/1/2013
Development of a mother-child database for drug exposure and adverse event detection in the Military Health SystemThe aim of this study was to develop a mother-child linked database consisting of all eligible active duty military personnel, retirees, and their dependents in order to conduct medication-related analyses to improve the safety and quality of care in the Military Health System (MHS).5/24/2015
Active surveillance of postmarket medical product safety in the Federal Partners' CollaborationAfter half a century of monitoring voluntary reports of medical product adverse events, the Food and Drug Administration (FDA) has launched a long-term project to build an adverse events monitoring system, the Sentinel System, which can access and evaluate electronic health care data to help monitor the safety of regulated medical products once they are marketed.11/1/2012